Drugs / Durvalumab
Durvalumab
also known as
MEDI4736 · Imfinzi · durva · MEDI4736 (Durvalumab) · DUR · Durvalumab (Imfimzi) · Durvalumab (MEDI-4736) · durvalumab Injection [Imfinzi] · +3 more
Monoclonal antibody targets CD274 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 15 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (13) | US (FDA) | IMFINZI | — | 2018-02-16 – 2026-05-28 | fda.gov ↗ |
| Approved | EU (EMA) | Imfinzi | — | 2018-09-21 | europa.eu ↗ |
| Approved | US (FDA) | IMFINZI | — | 2017-05-01 | fda.gov ↗ |
Trials 729 · started per year
today
US approved 2017
EU approved 2018
1
1
4
20
36
62
81
90
73
73
73
51
46
55
36
23
3
20102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 011 trials | ||||||
| Phase 0 | NCT06824363 | May 2026 → Jan 2027 expected | esophageal adenocarcinoma, gastric adenocarcinoma | University of California, Irvine | Recruiting | No outcome recorded |
| Phase 0 | NCT04223648 | Aug 2020 → Feb 2022 | melanoma | Yale University | Withdrawn | No outcome recorded Stop: Business |
| Phase 0 | NCT04088032 | Oct 2019 → Dec 2020 | female breast carcinoma, hormone receptor-positive breast cancer | Alison Stopeck | Withdrawn | No outcome recorded |
| Phase 0 | NCT03818776 | Aug 2019 → Jan 2022 | non-small cell lung carcinoma | Case Comprehensive Cancer Center | Terminated | No outcome recorded |
| Phase 0 | NCT03618654 | Nov 2018 → Nov 2021 | oral cavity squamous cell carcinoma, oropharynx squamous cell carcinoma | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Completed | No outcome recorded |
| Phase 0 | NCT03235869 | Mar 2018 → Mar 2023 | primary cutaneous T-cell lymphoma | University of Michigan Rogel Cancer Center | Withdrawn | No outcome recorded |
| Phase 0 | NCT03215095 | Jul 2017 → Feb 2023 overdue | thyroid cancer | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 0 | NCT03132467 | Jun 2017 → Jan 2019 | Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer, progesterone-receptor positive breast cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 0 | NCT02812420 | Mar 2017 → Dec 2027 expected | hydronephrosis, infiltrating bladder urothelial carcinoma sarcomatoid variant, kidney pelvis sarcomatoid transitional cell carcinoma, micropapillary variant infiltrating bladder urothelial carcinoma +3 | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 0 | NCT02827838 | Jan 2017 → Apr 2022 | human papilloma virus infection, oral cavity squamous cell carcinoma, oropharynx squamous cell carcinoma | Wake Forest University Health Sciences | Terminated | No outcome recorded Stop: Enrollment |
| Phase 0 | NCT02802098 | May 2016 → Jun 2019 | breast cancer | Spanish National Cancer Research Centre | Completed | No outcome recorded |
| Phase 1126 trials · 5 met primary · 1 missed | ||||||
| Phase 1 | NCT05403723 | Jan 2027 → Feb 2028 | small cell lung carcinoma | University of Maryland, Baltimore | Suspended | No outcome recorded |
| Phase 1 | NCT07531095 | Apr 2026 → May 2028 expected | small cell lung carcinoma | Amgen | Recruiting | No outcome recorded |
| Phase 1 | NCT07391670 | Mar 2026 → Aug 2027 expected | cancer | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1 | NCT05733689 | Jun 2025 → Jun 2027 expected | gastroesophageal adenocarcinoma | University of California, Irvine | Recruiting | No outcome recorded |
| Phase 1 | NCT06963346 | Jun 2025 → Apr 2028 | urinary bladder cancer | H. Lee Moffitt Cancer Center and Research Institute | Suspended | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT06564623 | May 2025 → Mar 2029 expected | biliary tract cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
| Phase 1 | NCT06898957 | May 2025 → Jun 2031 expected | small cell lung carcinoma | Amgen | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06710223 | Jan 2025 → Jun 2027 expected | hepatocellular carcinoma | University of California, San Diego | Recruiting | No outcome recorded |
| Phase 1 | NCT06551142 | Sep 2024 → Oct 2028 expected | neoplasm | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 1 | NCT06058663 | Jun 2024 → Nov 2026 expected | intrahepatic cholangiocarcinoma | Mayo Clinic | Recruiting | No outcome recorded |
| Show all 126 trials opens the full record — a long page | ||||||
| Phase 1/297 trials · 3 met primary · 6 missed | ||||||
| Phase 1/2 | NCT07269158 | Dec 2025 → Sep 2029 expected | biliary tract neoplasm | Yonsei University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06608940 | Nov 2025 → Jan 2027 | hepatocellular carcinoma | Case Comprehensive Cancer Center | Withdrawn | No outcome recorded Stop: Business |
| Phase 1/2 | NCT07174583 | Oct 2025 → Jul 2029 expected | small cell lung carcinoma | IDEAYA Biosciences | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06911255 | Apr 2025 → Mar 2028 expected | hepatocellular carcinoma | Yoon Jun Kim | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06287775 | Apr 2025 → Jul 2029 expected | small cell lung carcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06780137 | Feb 2025 → Feb 2029 expected | small cell lung carcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06508216 | Jul 2024 → Dec 2025 overdue | breast cancer | Gustave Roussy, Cancer Campus, Grand Paris | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05932199 | Jul 2024 → May 2028 expected | mesothelioma | Baylor College of Medicine | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06255262 | Feb 2024 → Oct 2025 | biliary tract cancer | China Medical University, China | Unknown | No outcome recorded |
| Phase 1/2 | NCT06027086 | Feb 2024 → Sep 2028 expected | fibrolamellar hepatocellular carcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05927142 | Jan 2024 → Dec 2026 expected | pancreatic ductal adenocarcinoma | Joachim Aerts, MD PhD | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05451173 | Oct 2023 → Dec 2025 | non-small cell lung carcinoma | Alexander Chi | Unknown | No outcome recorded |
| Phase 1/2 | NCT05886439 | May 2023 → May 2027 expected | lung cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04989218 | Jan 2023 → Mar 2024 | cholangiocarcinoma | University of Alabama at Birmingham | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT05327582 | Apr 2022 → Apr 2023 | biliary tract cancer, malignant pancreatic neoplasm | Chinese PLA General Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT05325684 | Apr 2022 → Dec 2023 | — | The Affiliated Hospital of Qingdao University | Unknown | No outcome recorded |
| Phase 1/2 | NCT04106115 | Mar 2022 → Mar 2027 expected | urinary bladder cancer | University College, London | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04781192 | Mar 2022 → Nov 2025 overdue | biliary tract cancer | University of Kansas Medical Center | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04711824 | Mar 2022 → Jul 2026 overdue | breast cancer, metastatic malignant neoplasm in the brain | Colette Shen | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06074029 | Dec 2021 → Dec 2023 | biliary tract cancer, immunotherapy induced hypophysitis | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT05187338 | Nov 2021 → Oct 2029 expected | breast cancer, cervical cancer, colorectal cancer, esophageal cancer +7 | Second Affiliated Hospital of Guangzhou Medical University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05120622 | Sep 2021 → May 2022 | bladder carcinoma in situ | University of British Columbia | Withdrawn | No outcome recorded Stop: Business |
| Phase 1/2 | NCT04748419 | Jul 2021 → Sep 2025 | non-small cell lung carcinoma | University of Nebraska | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT04646837 | May 2021 → May 2024 | non-small cell lung carcinoma | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT04902040 | Apr 2021 → Feb 2025 | cutaneous melanoma, cutaneous neuroendocrine carcinoma, non-small cell lung carcinoma, renal cell adenocarcinoma +1 | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT04696848 | Feb 2021 → Mar 2023 | colorectal cancer | Tae Won Kim | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT05267392 | Feb 2021 → Jul 2023 | non-small cell lung carcinoma | Instituto Portugues de Oncologia, Francisco Gentil, Porto | Unknown | No outcome recorded |
| Phase 1/2 | NCT04728230 | Jan 2021 → Dec 2027 expected | small cell lung carcinoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04538742 | Dec 2020 → Jan 2025 overdue | breast cancer | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03245541 | Aug 2020 → Sep 2027 expected | pancreatic adenocarcinoma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04124991 | Jun 2020 → Jul 2022 | hepatocellular carcinoma | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT04257448 | May 2020 → Jul 2024 | pancreatic ductal adenocarcinoma | GWT-TUD GmbH | Completed | No outcome recorded |
| Phase 1/2 | NCT04019288 | Dec 2019 → Oct 2024 | fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT03970616 | Sep 2019 → Apr 2023 | hepatocellular carcinoma | AVEO Pharmaceuticals, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT03802071 | Sep 2019 → Aug 2022 | sarcoma | Yonsei University | Completed | No outcome recorded |
| Phase 1/2 | NCT04068610 | Sep 2019 → Oct 2022 overdue | colorectal cancer | MedImmune LLC | Active not recruiting | Missed primary |
| Phase 1/2 | NCT03871036 | May 2019 → Sep 2023 | urothelial carcinoma | The Netherlands Cancer Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT03829007 | Apr 2019 → Dec 2020 | head and neck cancer | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT03581487 | Apr 2019 → Oct 2025 | non-small cell lung carcinoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT03837899 | Mar 2019 → Feb 2023 overdue | childhood malignant neoplasm, hematopoietic and lymphoid cell neoplasm | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03694236 | Feb 2019 → May 2027 expected | — | Yonsei University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03742102 | Dec 2018 → Nov 2024 overdue | triple-negative breast carcinoma | AstraZeneca | Active not recruiting | Missed primary |
| Phase 1/2 | NCT03549715 | Dec 2018 → Jun 2024 | infiltrating bladder urothelial carcinoma | Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie | Unknown | Mixed |
| Phase 1/2 | NCT03539822 | Oct 2018 → Jun 2028 expected | colorectal cancer, esophageal adenocarcinoma, gastric cancer, hepatocellular carcinoma | Anwaar Saeed | Recruiting | Met primary |
| Phase 1/2 | NCT03618134 | Oct 2018 → Jun 2023 | human papilloma virus infection, oropharynx squamous cell carcinoma | Jonsson Comprehensive Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT03721679 | Sep 2018 → Jan 2021 | — | Oncovir, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT03376659 | Aug 2018 → Aug 2021 | colorectal adenocarcinoma, metastasis from malignant tumor of colon, pancreatic adenocarcinoma | Georgetown University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT03283605 | Jul 2018 → Jul 2024 | head and neck squamous cell carcinoma | University of Montreal Hospital Centre (CHUM) | Unknown | No outcome recorded |
| Phase 1/2 | NCT03594396 | Jun 2018 → Dec 2025 overdue | breast neoplasm | Seoul National University Hospital | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03611556 | Jun 2018 → Jul 2022 | pancreatic adenocarcinoma | MedImmune LLC | Completed | Missed primary |
| Phase 1/2 | NCT03518606 | Jun 2018 → Apr 2022 | breast cancer, cervical cancer, head and neck cancer, prostate cancer | UNICANCER | Completed | No outcome recorded |
| Phase 1/2 | NCT03751761 | Jun 2018 → Aug 2023 | gastric cancer | Asan Medical Center | Completed | Met primary |
| Phase 1/2 | NCT03161223 | May 2018 → Feb 2023 overdue | T-cell non-Hodgkin lymphoma | University of Virginia | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03522584 | May 2018 → Dec 2021 | head and neck squamous cell carcinoma | University of Washington | Terminated | No outcome recorded |
| Phase 1/2 | NCT03051906 | Jan 2018 → Jan 2022 | head and neck neoplasm | Careggi University Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT03164772 | Dec 2017 → Oct 2021 | non-small cell lung carcinoma | Ludwig Institute for Cancer Research | Completed | No outcome recorded |
| Phase 1/2 | NCT03310619 | Dec 2017 → Feb 2023 | diffuse large B-cell lymphoma, follicular lymphoma | Celgene Corporation | Completed | No outcome recorded |
| Phase 1/2 | NCT03308396 | Dec 2017 → Dec 2022 overdue | clear cell renal carcinoma | Ajjai Alva, MD | Active not recruiting | Missed primary |
| Phase 1/2 | NCT03206073 | Dec 2017 → Sep 2020 | colorectal adenocarcinoma, refractory malignant neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT03317158 | Nov 2017 → Dec 2028 expected | urinary bladder cancer, urothelial carcinoma | Noah Hahn, M.D. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03249142 | Oct 2017 → Dec 2024 | ovarian cancer | ARCAGY/ GINECO GROUP | Completed | No outcome recorded |
| Phase 1/2 | NCT03148327 | Oct 2017 → Apr 2026 | non-small cell lung carcinoma | Jonsson Comprehensive Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT02963831 | Sep 2017 → Jun 2022 | appendix cancer, ovarian carcinoma | Ludwig Institute for Cancer Research | Completed | No outcome recorded |
| Phase 1/2 | NCT03202758 | Aug 2017 → Jan 2023 | colorectal cancer | Centre Georges Francois Leclerc | Completed | Met primary |
| Phase 1/2 | NCT03323398 | Aug 2017 → Aug 2021 | ovarian cancer | ModernaTX, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT03162224 | Jun 2017 → Mar 2021 | head and neck cancer, human papilloma virus infection | MedImmune LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT03116529 | Jun 2017 → Jun 2024 | soft tissue sarcoma | University of Maryland, Baltimore | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT03212469 | Jun 2017 → Feb 2025 | esophageal cancer, head and neck squamous cell carcinoma, lung cancer | Gustave Roussy, Cancer Campus, Grand Paris | Completed | No outcome recorded |
| Phase 1/2 | NCT02898116 | May → Aug 2017 | non-small cell lung carcinoma | Ludwig Institute for Cancer Research | Completed | No outcome recorded |
| Phase 1/2 | NCT03356860 | Apr 2017 → Nov 2022 | luminal B breast carcinoma, triple-negative breast carcinoma | Grand Hôpital de Charleroi | Completed | No outcome recorded |
| Phase 1/2 | NCT03011814 | Mar 2017 → Apr 2030 expected | Sezary syndrome, folliculotropic mycosis fungoides, mature T-cell and NK-cell non-Hodgkin lymphoma, mycosis fungoides +1 | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02866747 | Jan 2017 → Nov 2024 | glioblastoma | Institut Claudius Regaud | Completed | No outcome recorded |
| Phase 1/2 | NCT02643303 | Dec 2016 → Feb 2022 | breast cancer, cutaneous neuroendocrine carcinoma, head and neck squamous cell carcinoma, kidney cancer +6 | Ludwig Institute for Cancer Research | Completed | No outcome recorded |
| Phase 1/2 | NCT02891161 | Nov 2016 → Aug 2019 | urothelial carcinoma | Monika Joshi, MD | Terminated | No outcome recorded |
| Phase 1/2 | NCT02628132 | Nov 2016 → Dec 2019 | breast cancer | King Faisal Specialist Hospital & Research Center | Completed | No outcome recorded |
| Phase 1/2 | NCT02962063 | Nov 2016 → Nov 2026 expected | esophageal adenocarcinoma, gastroesophageal junction adenocarcinoma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02726997 | Jul 2016 → Dec 2027 expected | fallopian tube carcinoma, primary peritoneal carcinoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02735239 | Jun 2016 → Jun 2022 | esophageal cancer | Ludwig Institute for Cancer Research | Completed | No outcome recorded |
| Phase 1/2 | NCT02805660 | Jun 2016 → Dec 2019 | cancer of unknown primary site | Mirati Therapeutics Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT02733042 | May 2016 → Mar 2019 | B-cell chronic lymphocytic leukemia | Celgene Corporation | Completed | No outcome recorded |
| Phase 1/2 | NCT02685826 | Apr 2016 → Dec 2017 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 1/2 | NCT02583477 | Mar 2016 → Jul 2018 | pancreatic ductal adenocarcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 1/2 | NCT02734004 | Mar 2016 → Sep 2021 overdue | breast disorder, gastric cancer, ovarian disorder, small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02671435 | Feb 2016 → Oct 2021 overdue | cancer | MedImmune LLC | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02431559 | Dec 2015 → Dec 2018 | ovarian cancer | Ludwig Institute for Cancer Research | Completed | No outcome recorded |
| Phase 1/2 | NCT02489448 | Nov 2015 → Jun 2021 | breast neoplasm | Yale University | Completed | No outcome recorded |
| Phase 1/2 | NCT02499328 | Aug 2015 → Feb 2020 | head and neck squamous cell carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 1/2 | NCT02484404 | Jun 2015 → Oct 2027 expected | breast cancer, colorectal cancer | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02401048 | May 2015 → Nov 2017 | diffuse large B-cell lymphoma, follicular lymphoma | Pharmacyclics LLC. | Completed | No outcome recorded |
| Phase 1/2 | NCT02291055 | Apr 2015 → Jul 2019 | cervical cancer, head and neck cancer | Advaxis, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT02340975 | Mar 2015 → Apr 2019 | adenocarcinoma | MedImmune LLC | Completed | Missed primary |
| Phase 1/2 | NCT02311361 | Mar 2015 → Oct 2019 | malignant pancreatic neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT02403271 | Mar 2015 → Aug 2017 | breast cancer, malignant pancreatic neoplasm, non-small cell lung carcinoma | Pharmacyclics LLC. | Completed | No outcome recorded |
| Phase 1/2 | NCT02318277 | Jan 2015 → Aug 2019 | head and neck cancer, lung cancer, urothelial carcinoma | Incyte Corporation | Completed | No outcome recorded |
| Phase 1/2 | NCT02205333 | Aug 2014 → Apr 2016 | aggressive B-cell non-Hodgkin lymphoma, cancer | MedImmune LLC | Terminated | No outcome recorded |
| Phase 1/2 | NCT02118337 | May 2014 → Mar 2020 | clear cell renal carcinoma, high grade malignant neoplasm | MedImmune LLC | Completed | Missed primary |
| Phase 1/2 | NCT01693562 | Sep 2012 → Feb 2020 | cancer | MedImmune LLC | Completed | No outcome recorded |
| Phase 2403 trials · 9 met primary · 18 missed | ||||||
| Phase 2 | NCT07639528 | Dec 2027 → Dec 2030 expected | intrahepatic cholangiocarcinoma | Northwestern University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07603856 | Dec 2026 → Jun 2030 expected | non-small cell lung carcinoma | University of Chicago | Recruiting | No outcome recorded |
| Phase 2 | NCT07459634 | Nov 2026 → Jan 2028 expected | small cell lung carcinoma | Jazz Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 2 | NCT05253131 | Nov 2026 → Nov 2031 expected | malignant peripheral nerve sheath tumor, neurofibromatosis type 1 | University of Alabama at Birmingham | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07780838 | Nov 2026 → Dec 2027 expected | carcinoma of the ampulla of vater, distal biliary tract carcinoma, gallbladder carcinoma, intrahepatic cholangiocarcinoma | Ohio State University Comprehensive Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT06855225 | Oct 2026 → May 2027 expected | combined hepatocellular carcinoma and cholangiocarcinoma | Mehmet Akce | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07247786 | Sep 2026 → Dec 2031 expected | non-small cell lung carcinoma | Fundación GECP | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07146230 | Sep 2026 → Apr 2028 expected | non-small cell lung carcinoma | Montefiore Medical Center | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07507968 | Jul 2026 → Feb 2030 expected | gastroesophageal adenocarcinoma | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07339059 | Jun 2026 → Feb 2029 expected | small cell lung carcinoma | Bindu R Potugari | Recruiting | No outcome recorded |
| Show all 403 trials opens the full record — a long page | ||||||
| Phase 2/34 trials | ||||||
| Phase 2/3 | NCT06904170 | Nov 2025 → Sep 2029 expected | hepatocellular carcinoma | UNICANCER | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04628767 | Nov 2021 → Sep 2027 expected | renal pelvis/ureter urothelial carcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03258554 | Apr 2018 → Sep 2022 | hypopharynx squamous cell carcinoma, laryngeal squamous cell carcinoma, oral cavity squamous cell carcinoma, oropharynx squamous cell carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2/3 | NCT02766335 | Jul 2014 → Sep 2018 | non-small cell squamous lung carcinoma | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 376 trials · 14 met primary · 10 missed | ||||||
| Phase 3 | NCT07637513 | Jan 2027 → Nov 2037 expected | small cell lung carcinoma | PrECOG, LLC. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07166406 | Feb 2026 → Mar 2029 expected | hepatocellular carcinoma | NRG Oncology | Recruiting | No outcome recorded |
| Phase 3 | NCT07027436 | Nov 2025 → Oct 2027 expected | hepatocellular carcinoma | Hamilton Health Sciences Corporation | Recruiting | No outcome recorded |
| Phase 3 | NCT06992609 | Sep 2025 → Jun 2029 expected | small cell lung carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT06732401 | Aug 2025 → Jun 2028 expected | non-small cell lung carcinoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06841172 | Jul 2025 → Jul 2027 expected | hepatocellular carcinoma | Shandong Cancer Hospital and Institute | Recruiting | No outcome recorded |
| Phase 3 | NCT06498635 | Apr 2025 → Jul 2039 expected | non-small cell lung carcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 3 | NCT06284317 | Jan 2025 → Oct 2029 expected | non-small cell lung carcinoma | ETOP IBCSG Partners Foundation | Recruiting | No outcome recorded |
| Phase 3 | NCT06746116 | Dec 2024 → Nov 2028 expected | endometrial cancer | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06719336 | Dec 2024 → Dec 2028 expected | small cell lung carcinoma | Anhui Shi, MD | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06282575 | Jul 2024 → Dec 2028 expected | biliary tract cancer | Jazz Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT06058377 | Nov 2023 → May 2032 expected | female breast carcinoma, hormone receptor-positive breast cancer | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 3 | NCT06103864 | Nov 2023 → Jul 2027 expected | breast cancer | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT06112379 | Nov 2023 → Nov 2028 expected | breast cancer | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06031597 | Sep 2023 → Dec 2025 | non-small cell lung carcinoma | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT05771480 | Aug 2023 → Oct 2025 overdue | biliary tract cancer | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05943106 | Aug 2023 → Jun 2025 overdue | urinary bladder cancer | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05924880 | Jul 2023 → Feb 2025 | biliary tract cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT05557838 | Feb 2023 → Sep 2026 overdue | hepatocellular carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05687266 | Dec 2022 → Nov 2027 expected | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05629585 | Nov 2022 → Sep 2027 expected | breast cancer | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05450692 | Sep 2022 → Oct 2025 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | Missed primary |
| Phase 3 | NCT04637594 | May 2022 → Jun 2024 overdue | renal pelvis urothelial carcinoma | Alliance for Clinical Trials in Oncology | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05298423 | May 2022 → Jun 2026 overdue | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05303532 | Apr 2022 → Dec 2026 expected | cancer | AstraZeneca | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT05301842 | Mar 2022 → Feb 2026 overdue | hepatocellular carcinoma | AstraZeneca | Active not recruiting | Met primary |
| Phase 3 | NCT05211895 | Feb 2022 → Jul 2028 expected | non-small cell lung carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT05221840 | Feb 2022 → Sep 2026 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04774380 | Nov 2021 → Jun 2023 | small cell lung carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT05255653 | Nov 2021 → Jan 2030 expected | endometrial cancer | Leiden University Medical Center | Recruiting | No outcome recorded |
| Phase 3 | NCT05043090 | Oct 2021 → Dec 2025 overdue | papillary renal cell carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04585490 | Aug 2021 → Dec 2026 expected | non-small cell lung carcinoma | Stanford University | Recruiting | No outcome recorded |
| Phase 3 | NCT04960709 | Aug 2021 → Mar 2026 overdue | urinary bladder carcinoma | AstraZeneca | Active not recruiting | Met primary |
| Phase 3 | NCT04866017 | Jun 2021 → Oct 2023 | non-small cell lung carcinoma | BeiGene | Terminated | No outcome recorded |
| Phase 3 | NCT03673735 | Jun 2021 → Jul 2026 | head and neck squamous cell carcinoma | European Organisation for Research and Treatment of Cancer - EORTC | Withdrawn | No outcome recorded |
| Phase 3 | NCT04334759 | Feb 2021 → Jun 2025 | malignant pleural mesothelioma | PrECOG, LLC. | Completed | No outcome recorded |
| Phase 3 | NCT04712903 | Dec 2020 → Jun 2023 | small cell lung carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT04449861 | Dec 2020 → Mar 2023 | small cell lung carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT04642469 | Nov 2020 → May 2023 | non-small cell lung carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT04592913 | Nov 2020 → Dec 2024 overdue | gastroesophageal cancer | AstraZeneca | Active not recruiting | Met primary |
| Phase 3 | NCT04550260 | Oct 2020 → Jun 2027 expected | esophageal squamous cell carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04465968 | Sep 2020 → Aug 2027 expected | lung superior sulcus carcinoma, non-small cell lung carcinoma | National Cancer Center Hospital East | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT04385368 | Jul 2020 → Aug 2023 | non-small cell lung carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT04269200 | May 2020 → Jul 2024 overdue | endometrial cancer | AstraZeneca | Active not recruiting | Met primary |
| Phase 3 | NCT04092283 | Apr 2020 → Dec 2028 expected | non-small cell lung carcinoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03784014 | Oct 2019 → Dec 2023 | soft tissue sarcoma | French National Institute of Health and Medical Research | Completed | No outcome recorded |
| Phase 3 | NCT04026412 | Oct 2019 → Mar 2024 | non-small cell lung carcinoma | Bristol-Myers Squibb | Completed | Missed primary |
| Phase 3 | NCT03847428 | Apr 2019 → May 2026 | hepatocellular carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT03875235 | Apr 2019 → Aug 2021 overdue | biliary tract neoplasm | AstraZeneca | Active not recruiting | Met primary |
| Phase 3 | NCT03833154 | Mar 2019 → Oct 2028 expected | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03830866 | Feb 2019 → Jan 2022 | cervical carcinoma | AstraZeneca | Completed | Missed primary |
| Phase 3 | NCT03737643 | Jan 2019 → Mar 2025 overdue | ovarian carcinoma | AstraZeneca | Active not recruiting | Met primary |
| Phase 3 | NCT03800134 | Dec 2018 → Nov 2022 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | Met primary |
| Phase 3 | NCT03778957 | Nov 2018 → Sep 2023 overdue | hepatocellular carcinoma | AstraZeneca | Active not recruiting | Met primary |
| Phase 3 | NCT03706690 | Nov 2018 → Jun 2024 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | Met primary |
| Phase 3 | NCT03732677 | Nov 2018 → Apr 2024 overdue | urinary bladder carcinoma | AstraZeneca | Active not recruiting | Met primary |
| Phase 3 | NCT03703297 | Sep 2018 → Jan 2024 overdue | small cell lung carcinoma | AstraZeneca | Active not recruiting | Met primary |
| Phase 3 | NCT03682068 | Sep 2018 → Jun 2026 overdue | urothelial carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03288532 | Jul 2018 → Jul 2024 overdue | renal cell carcinoma | University College, London | Recruiting | No outcome recorded |
| Phase 3 | NCT03528694 | May 2018 → Apr 2025 overdue | non-invasive bladder urothelial carcinoma | AstraZeneca | Active not recruiting | Met primary |
| Phase 3 | NCT03519971 | Mar 2018 → Sep 2023 | non-small cell lung carcinoma | AstraZeneca | Completed | Missed primary |
| Phase 3 | NCT03298451 | Oct 2017 → Aug 2021 overdue | hepatocellular carcinoma | AstraZeneca | Active not recruiting | Met primary |
| Phase 3 | NCT03084471 | Jun 2017 → Mar 2020 | high grade malignant neoplasm | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT03164616 | Jun 2017 → Mar 2021 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | Mixed |
| Phase 3 | NCT03043872 | Mar 2017 → Jan 2020 overdue | small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03003962 | Jan 2017 → Oct 2022 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | Mixed |
| Phase 3 | NCT02542293 | Nov 2015 → Sep 2020 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | Missed primary |
| Phase 3 | NCT02516241 | Nov 2015 → Jan 2020 overdue | urothelial carcinoma | AstraZeneca | Active not recruiting | Missed primary |
| Phase 3 | NCT02551159 | Oct 2015 → Jul 2020 | head and neck squamous cell carcinoma | AstraZeneca | Completed | Missed primary |
| Phase 3 | NCT02369874 | Sep 2015 → Sep 2018 | head and neck squamous cell carcinoma | AstraZeneca | Completed | Missed primary |
| Phase 3 | NCT02453282 | Jul 2015 → Oct 2018 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | Mixed |
| Phase 3 | NCT02454933 | Jul 2015 → Aug 2017 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT04116047 | Jul 2015 → Dec 2026 expected | oropharynx cancer | University of Birmingham | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02273375 | Feb 2015 → Jul 2025 | non-small cell lung carcinoma | Canadian Cancer Trials Group | Completed | Missed primary |
| Phase 3 | NCT02352948 | Jan 2015 → Feb 2018 | non-small cell lung carcinoma | AstraZeneca | Completed | Missed primary |
| Phase 3 | NCT02125461 | May 2014 → Feb 2017 | non-small cell lung carcinoma | AstraZeneca | Completed | Met primary |
| Phase 45 trials | ||||||
| Phase 4 | NCT06908070 | Dec 2024 → Dec 2026 expected | non-small cell lung carcinoma | Idris Bahce | Recruiting | No outcome recorded |
| Phase 4 | NCT06031233 | Sep 2023 → Jul 2028 expected | — | Isala | Recruiting | No outcome recorded |
| Phase 4 | NCT04416633 | Nov 2021 → Oct 2023 | non-small cell lung carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT04356222 | Jun 2020 → Jun 2023 | neoplastic meningitis | Hui Bu | Unknown | No outcome recorded |
| Phase 4 | NCT04078152 | Sep 2019 → Oct 2022 | cancer | AstraZeneca | Completed | No outcome recorded |
| Phase not applicable6 trials | ||||||
| — | NCT06611345 | Oct 2024 → Oct 2026 expected | biliary tract cancer | Jiangsu Healthy Life Innovation Medical Technology Co., Ltd | Recruiting | No outcome recorded |
| — | NCT04517227 | Jul 2021 → Jun 2025 | hepatocellular carcinoma | Fudan University | Unknown | No outcome recorded |
| — | NCT04851132 | Mar 2021 → Mar 2023 | esophageal squamous cell carcinoma | Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
| — | NCT04443322 | Sep 2020 → Dec 2021 | hepatocellular carcinoma | RenJi Hospital | Unknown | No outcome recorded |
| — | NCT04444193 | Aug 2020 → May 2021 | endometrial cancer | Shanghai First Maternity and Infant Hospital | Unknown | No outcome recorded |
| — | NCT02563925 | Sep 2015 → Jul 2021 | breast cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT05345678 | — | hepatocellular carcinoma | AstraZeneca | Approved for marketing | No outcome recorded |
| Comparator or background therapy91 trials | ||||||
| Phase 1 | NCT07700420 Background | Aug 2026 → Oct 2027 expected | esophageal cancer, gastroesophageal cancer | University of Texas Southwestern Medical Center | Recruiting | No outcome recorded |
| Phase 1 | NCT07619313 Background | Jun 2026 → Jun 2027 expected | cholangiocarcinoma, pancreatic ductal adenocarcinoma | Jonsson Comprehensive Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07107750 Background | Mar 2026 → Jun 2030 expected | biliary tract cancer | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 1 | NCT05358691 Background | Nov 2024 → Dec 2027 | lung carcinoma | Rutgers, The State University of New Jersey | Withdrawn | No outcome recorded |
| Phase 1 | NCT06546969 Background | Oct 2024 → Dec 2027 expected | cholangiocarcinoma | University of Maryland, Baltimore | Recruiting | No outcome recorded |
| Phase 1 | NCT06302426 Background | Jul 2024 → Oct 2026 expected | neoplasm | Inimmune Corporation | Recruiting | No outcome recorded |
| Phase 1 | NCT06124118 Background | Apr 2024 → Nov 2026 expected | non-small cell lung carcinoma | University of Utah | Recruiting | No outcome recorded |
| Phase 1 | NCT05154994 Background | Jan 2022 → Aug 2026 overdue | infiltrating bladder urothelial carcinoma sarcomatoid variant | University of Utah | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05136846 Background | Dec 2021 → Dec 2026 expected | non-small cell lung carcinoma | Ohio State University Comprehensive Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT04900818 Background | Jun 2021 → Dec 2026 expected | biliary tract cancer, esophageal adenocarcinoma, gastric cancer, gastroesophageal cancer +2 | I-Mab Biopharma US Limited | Recruiting | No outcome recorded |
| Phase 1 | NCT05157542 Background | Jun 2021 → Jun 2023 | non-small cell lung carcinoma | Juan LI, MD | Unknown | No outcome recorded |
| Phase 1 | NCT04387084 Background | Aug 2020 → Mar 2027 expected | skin cancer | University of Southern California | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03946800 Background | May 2019 → Aug 2023 | cancer | MedImmune LLC | Completed | No outcome recorded |
| Phase 1 | NCT02890368 Background | Sep 2016 → Mar 2020 | breast carcinoma, cutaneous neuroendocrine carcinoma, melanoma, mycosis fungoides +2 | Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT02900157 Background | Aug 2016 → Jan 2020 | cancer | MedImmune LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT06694454 Background | Oct 2026 → Dec 2031 | non-small cell lung carcinoma | National Cancer Institute (NCI) | Suspended | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT06939036 Background | Jul → Dec 2025 | cutaneous neuroendocrine carcinoma, small cell lung carcinoma | Ariceum Therapeutics GmbH | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT06548412 Background | Jan 2025 → May 2027 expected | biliary tract cancer | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06501625 Background | Dec 2024 → Jul 2026 overdue | IDH-mutant anaplastic astrocytoma | Servier | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06111326 Background | Oct 2023 → Aug 2024 | hepatocellular carcinoma | Biocity Biopharmaceutics Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT04954599 Background | May 2023 → Feb 2027 expected | cancer of unknown primary site | Maastricht University Medical Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03942328 Background | Sep 2019 → Aug 2030 expected | hepatocellular carcinoma, intrahepatic cholangiocarcinoma | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03732274 Background | Feb 2019 → May 2024 | non-small cell lung carcinoma | MedPacto, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT03616886 Background | Dec 2018 → May 2021 overdue | triple-negative breast carcinoma | Jules Bordet Institute | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03784066 Comparator | Aug 2018 → Mar 2025 overdue | oral cavity squamous cell carcinoma | Universitaire Ziekenhuizen KU Leuven | Active not recruiting | No outcome recorded |
| Phase 2 | NCT07625930 Background | Jan 2027 → Apr 2029 expected | gastroesophageal adenocarcinoma | McGill University Health Centre/Research Institute of the McGill University Health Centre | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07332351 Background | Dec 2026 → Jan 2027 expected | infiltrating bladder urothelial carcinoma | University of Washington | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07858253 Background | Oct 2026 → Oct 2030 expected | lung carcinoma | Anusha Chidharla, MD | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07766187 Background | Oct 2026 → Aug 2032 expected | intrahepatic cholangiocarcinoma | University of Wisconsin, Madison | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06274879 Background | May 2026 → Dec 2029 expected | bile duct cancer | Insel Gruppe AG, University Hospital Bern | Recruiting | No outcome recorded |
| Phase 2 | NCT07175441 Comparator | Apr 2026 → Apr 2027 expected | hepatocellular carcinoma | Riboscience, LLC. | Recruiting | No outcome recorded |
| Phase 2 | NCT07036380 Background | Dec 2025 → Nov 2028 expected | biliary tract cancer | Centre Hospitalier Universitaire de Besancon | Recruiting | No outcome recorded |
| Phase 2 | NCT06769126 Background | Nov 2025 → Dec 2028 expected | small cell lung carcinoma | SWOG Cancer Research Network | Recruiting | No outcome recorded |
| Phase 2 | NCT07172412 Background | Nov 2025 → Dec 2027 expected | small cell lung carcinoma | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06880523 Background | Oct 2025 → Jan 2028 expected | hepatocellular carcinoma | Canadian Cancer Trials Group | Recruiting | No outcome recorded |
| Phase 2 | NCT06858735 Background | Jun 2025 → Nov 2028 expected | intrahepatic cholangiocarcinoma | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT06773910 Comparator | Mar 2025 → May 2032 expected | small cell lung carcinoma | SCRI Development Innovations, LLC | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06667908 Background | Dec 2024 → Dec 2028 expected | non-small cell lung carcinoma | Johnson & Johnson Enterprise Innovation Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT06102057 Background | Jul 2024 → Jun 2026 overdue | non-small cell lung carcinoma | TheraOp | Recruiting | No outcome recorded |
| Phase 2 | NCT06502080 Background | Jul 2024 → Jun 2027 expected | biliary tract cancer | Shanghai Zhongshan Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05718297 Comparator | Jun → Sep 2024 | non-small cell lung carcinoma | ETOP IBCSG Partners Foundation | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT06333678 Comparator | Mar 2024 → Jan 2026 | non-small cell lung carcinoma | Memorial Sloan Kettering Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT05161533 Background | Oct 2023 → Oct 2024 | small cell lung carcinoma | University of Washington | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT05451043 Background | Jul 2023 → Oct 2026 expected | cholangiocarcinoma, hepatocellular carcinoma, malignant pancreatic neoplasm | AHS Cancer Control Alberta | Recruiting | No outcome recorded |
| Phase 2 | NCT05712356 Background | May 2023 → Apr 2026 | gallbladder carcinoma, intrahepatic cholangiocarcinoma | Lisata Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT05632809 Background | Jan 2023 → Dec 2027 expected | lung cancer | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT05198830 Background | Dec 2022 → Jun 2027 expected | lung adenocarcinoma, lung large cell carcinoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04105270 Background | Nov 2022 → Jan 2028 expected | lung adenocarcinoma | Masonic Cancer Center, University of Minnesota | Recruiting | No outcome recorded |
| Phase 2 | NCT04905316 Background | May 2021 → Jul 2026 | non-small cell lung carcinoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT04660097 Background | May 2021 → Jun 2024 | small cell lung carcinoma | Henan Cancer Hospital | Completed | No outcome recorded |
| Phase 2 | NCT04699838 Background | Apr 2021 → Jan 2027 expected | small cell lung carcinoma | Muhammad Furqan | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03606967 Background | Apr 2021 → Dec 2026 expected | invasive breast carcinoma, triple-negative breast carcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2 | NCT04621370 Comparator | Dec 2020 → Jun 2025 | rectum adenocarcinoma | Cancer Research UK, Glasgow | Unknown | No outcome recorded |
| Phase 2 | NCT03847649 Comparator | Mar 2020 → Apr 2030 expected | cancer | Canadian Cancer Trials Group | Recruiting | No outcome recorded |
| Phase 2 | NCT03768570 Comparator | Oct 2019 → Oct 2026 expected | urinary bladder cancer | Canadian Cancer Trials Group | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03959293 Background | Jul 2019 → Mar 2022 overdue | gastric adenocarcinoma | Federation Francophone de Cancerologie Digestive | Active not recruiting | Missed primary |
| Phase 2 | NCT03840902 Comparator | Apr 2019 → Feb 2023 | non-small cell lung carcinoma | EMD Serono Research & Development Institute, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT03994393 Comparator | Oct 2018 → Jun 2023 | lung cancer | University of Sydney | Unknown | No outcome recorded |
| Phase 2 | NCT03544723 Background | Oct 2018 → Jun 2022 | cancer, lymphoma | MultiVir, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT03057106 Comparator | Mar 2017 → Feb 2020 overdue | lung cancer | Canadian Cancer Trials Group | Active not recruiting | Missed primary |
| Phase 2 | NCT02794883 Comparator | Nov 2016 → May 2018 | glioblastoma | Northwestern University | Completed | No outcome recorded |
| Phase 2 | NCT02452463 Background | Jun 2015 → Jun 2019 | non-small cell lung carcinoma, radiation pneumonitis | Roswell Park Cancer Institute | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2/3 | NCT06214572 Comparator | Mar 2024 → Jul 2029 expected | gallbladder cancer | Tata Memorial Centre | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06109272 Comparator | Jan 2024 → Jan 2027 expected | hepatocellular carcinoma | AbbVie | Active not recruiting | No outcome recorded |
| Phase 3 | NCT07796100 Comparator | Dec 2026 → Jun 2030 expected | small cell lung carcinoma | Zai Lab (Shanghai) Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07672223 Comparator | Jun 2026 → Sep 2029 expected | non-small cell lung carcinoma | CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07710885 Comparator | Jun 2026 → Apr 2030 expected | biliary tract cancer | Taiho Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07554339 Background | Jun 2026 → Dec 2032 expected | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT07361497 Comparator | Mar 2026 → Sep 2030 expected | non-small cell lung carcinoma | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 3 | NCT07229625 Comparator | Jan 2026 → Dec 2029 expected | biliary tract cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07195695 Comparator | Jan 2026 → Feb 2032 expected | non-small cell lung carcinoma | Boehringer Ingelheim | Recruiting | No outcome recorded |
| Phase 3 | NCT07221253 Comparator | Dec 2025 → Jul 2029 expected | biliary tract cancer | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT06840782 Background | Sep 2025 → Feb 2030 expected | non-small cell lung carcinoma | Gustave Roussy, Cancer Campus, Grand Paris | Recruiting | No outcome recorded |
| Phase 3 | NCT07005128 Background | Aug 2025 → Jan 2029 expected | small cell lung carcinoma | Amgen | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06890598 Background | Mar 2025 → May 2029 expected | non-small cell lung carcinoma | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 3 | NCT06591520 Comparator | Oct 2024 → Oct 2026 expected | biliary tract cancer | Akeso | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06467357 Comparator | Aug 2024 → Jun 2028 expected | biliary tract cancer | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT06211036 Background | Jun 2024 → Jul 2027 expected | small cell lung carcinoma | Amgen | Active not recruiting | Met primary |
| Phase 3 | NCT05624996 Background | Jul 2023 → Oct 2031 expected | non-small cell lung carcinoma | NRG Oncology | Recruiting | No outcome recorded |
| Phase 3 | NCT05170204 Comparator | Nov 2022 → Jun 2030 expected | non-small cell lung carcinoma | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05223647 Background | Jan 2022 → Sep 2025 | small cell lung carcinoma | Norwegian University of Science and Technology | Terminated | No outcome recorded |
| Phase 3 | NCT04597671 Background | Dec 2021 → Dec 2028 expected | non-small cell lung carcinoma | Association NVALT Studies | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04513925 Comparator | Aug 2020 → May 2025 | non-small cell lung carcinoma | Hoffmann-La Roche | Completed | Missed primary |
| Phase 3 | NCT04380636 Comparator | Jul 2020 → May 2027 expected | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT01993810 Background | Jan 2014 → Nov 2028 expected | non-small cell lung carcinoma | Radiation Therapy Oncology Group | Active not recruiting | No outcome recorded |
| — | NCT07853690 Background | Sep 2026 → Sep 2027 expected | biliary tract cancer | NYU Langone Health | Not yet recruiting | No outcome recorded |
| — | NCT06484491 Background | Sep 2025 → Oct 2027 expected | non-small cell lung carcinoma | University Medical Center Groningen | Recruiting | No outcome recorded |
| — | NCT06702566 Background | Jul 2024 → Jul 2026 overdue | acute leukemia, cancer | Tianjin Medical University Cancer Institute and Hospital | Recruiting | No outcome recorded |
| — | NCT05834413 Background | May 2023 → Jun 2027 expected | lung cancer | Shanghai University of Traditional Chinese Medicine | Recruiting | No outcome recorded |
| — | NCT04985851 Comparator | Sep 2021 → Jun 2024 | small cell lung carcinoma | Shanghai Chest Hospital | Unknown | No outcome recorded |
| — | NCT02492867 Background | Jan 2016 → Nov 2021 | non-small cell lung carcinoma | University of Michigan Rogel Cancer Center | Completed | No outcome recorded |
Press releases naming this drug 160 releases
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 830 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | durvalumab | “Standard of Care Drugs (at investigator's discretion) may include: pembrolizumab, nivolumab, cemiplimab, durvalumab, dostarlimab, avelumab, and atezolizumab, or other immune...” NCT07224971 ↗781“Successful organoids undergo drug sensitivity testing against a predefined panel of drugs (Gemcitabine + Cisplatin,Gemcitabine + Oxaliplatin,Durvalumab + Gemcitabine +...” NCT07351591 ↗ “The purpose of this study is to evaluate the safety, tolerability, and efficacy of MEDI4736 (durvalumab) alone and in combination with either tremelimumab or AZD9150 in adult...” NCT02549651 ↗ “The open-label, phase 1/2 ECHO-203 study evaluated the safety, tolerability, and efficacy of the IDO1 inhibitor epacadostat in combination with durvalumab, a human anti-PD-L1...” PMID 36309837 ↗ Oct 2022 “PD-L1 inhibitor Drug: Durvalumab OR pembrolizumab Durvalumab: During combination therapy: 1500 mg, Q3W, during combination therapy, on days 3-5 of each 3-week cycle (determined...” NCT07364305 ↗ “Durvalumab (1500 mg IV q4weeks) for 4 cycles in combination with tremelimumab. Then, durvalumab alone until confirmed disease progression, death, unacceptable toxicity,...” NCT03283605 ↗ “TTI-621 will be given in combination with one of the following programmed death-1 (PD-1) or programmed death-ligand-1 (PD-L1) inhibitors: nivolumab, pembrolizumab, durvalumab,...” NCT02890368 ↗ “combinations such as atezolizumab plus bevacizumab, tremelimumab plus durvalumab, or monotherapies such as lenvatinib, sorafenib, tislelizumab, durvalumab, or pembrolizumab, at...” NCT06841172 ↗ “This phase III study evaluated the efficacy of durvalumab (an anti-PD-L1 monoclonal antibody) or durvalumab plus tremelimumab (an anti-CTLA-4 monoclonal antibody) versus...” PMID 32294530 ↗ Apr 2020 “A Phase I/II Study of Paclitaxel Plus Carboplatin and Durvalumab (MEDI4736) With or Without Oleclumab (MEDI9447) for Previously Untreated Locally Recurrent Inoperable or...” NCT03616886 ↗ “Durvalumab is a human immunoglobulin G1 kappa monoclonal antibody which blocks the interaction between the programmed cell death ligand 1 (PD-L1) (a member of the B7 family)...” NCT05440864 ↗ |
| Known as | DUR | “Durvalumab (DUR) is a humanized monoclonal IgG1, anti-PD-L1 antibody with promising data in R/M HNSCC.” PMID 29594250 ↗ Feb 2018 |
| Known as | durva | “Previously, we showed targeting programmed death-ligand 1 (PD-L1) with durvalumab (durva) and radiation therapy (RT) combination was safe in BC.” PMID 36822667 ↗ Feb 20231“Patients will receive Durva 1120mg, which will be administered by infusion on day 1 of each 21-day cycle.” NCT06954480 ↗ |
| Known as | Durvalumab (Imfimzi) | “Durvalumab (Imfimzi)” NCT04989218 ↗ |
| Known as | Durvalumab (MEDI-4736) | “Durvalumab (MEDI-4736)” NCT03822351 ↗ |
| Known as | durvalumab Injection [Imfinzi] | “durvalumab Injection [Imfinzi]” NCT07174583 ↗ |
| Known as | Imfimzi | “Durvalumab (Imfimzi; MEDI4736; AstraZeneca) is a human monoclonal antibody” NCT04003246 ↗ |
| Known as | Imfinzi | “Durvalumab (Imfinzi) and stereotactic radiotherapy, with each fraction of radiotherapy is given every other day on a standard stereotactic ablative radiotherapy (SAbR) schedule...” NCT04786093 ↗9“This is a phase II, open label single arm, multicentre study of Tremelimumab in combination with Durvalumab (IMFINZI) in preoperative patients with resectable hepatocellular...” NCT05440864 ↗ “Durvalumab 50 MG/1 ML Intravenous Solution [IMFINZI]” NCT06418087 ↗ “Durvalumab (Imfinzi) immunotherapy” NCT05063565 ↗ “Durvalumab Injection [Imfinzi]” NCT04351256 ↗ “Durvalumab (Imfinzi)” NCT02423863 ↗ “Durvalumab (Imfinzi)” NCT03234153 ↗ “Durvalumab (Imfinzi)” NCT03721679 ↗ “Imfinzi” NCT02821754 ↗ |
| Known as | MEDI4736 | “This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) and domvanalimab...” NCT05211895 ↗147“This is a multicenter, open-label, dose-escalation, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, pharmacokinetic (PK),...” NCT02671435 ↗ “Phase I Study of Dual Immune Checkpoint Blockade (Anti-PD-L1 (Durvalumab) (MEDI4736) and Anti-CTLA4 (Tremelimumab) Plus Yttrium-90 (Y-90) Radioembolization & Stereotactic Body...” NCT03802747 ↗ “Durvalumab (MEDI4736) 1500mg Q4W in combination with tremelimumab for up to 4 doses/cycles, followed by durvalumab (MEDI4736) 1500mg Q4W for up to a maximum of 8 months with...” NCT03101475 ↗ “Phase II Randomized Study of Neoadjuvant Durvalumab (MEDI4736) Alone Versus Durvalumab (MEDI4736) With Olaparib (AZD2281) in Patients Ineligible for Cisplatin With...” NCT04579133 ↗ “An Investigator Sponsored Phase I Study of the Safety, Tolerability and Pharmacodynamics of Escalating Doses of Combination Treatment of AZD5363 + Olaparib + Durvalumab...” NCT03772561 ↗ “A Phase I Single-Arm Study of the Combination of Durvalumab (MEDI4736) and Vicineum (Oportuzumab Monatox, VB4-845) in Subjects With High Grade Non-Muscle-Invasive Bladder...” NCT03258593 ↗ “The CLEAN-DUCT / TRITICC-3 Trial - Phase IIa, Prospective, Single Arm, Open Label, Non-randomized, Multi-center Pilot Study of Durvalumab (MEDI4736) + Intraductal...” NCT06440993 ↗ “A Phase 2 Trial of Durvalumab (MEDI4736) and Tremelimumab With Chemotherapy in Metastatic EGFR Mutant Non-squamous Non-Small Cell Lung Cancer (NSCLC) Following Progression on...” NCT03994393 ↗ “Randomized Phase 2 Study of Preoperative Gemcitabine Plus Cisplatin With or Without Durvalumab (MEDI4736) Followed by Postoperative Durvalumab (MEDI4736) in Patients With...” NCT04308174 ↗ “Durvalumab (initially developed as MEDI4736) is a human monoclonal antibody of the immunoglobulin (Ig) G1 kappa subclass that inhibits binding of PD-L1 (B7-H1, CD274) to PD-1...” NCT04786093 ↗ |
| Known as | MEDI4736 (Durvalumab) | “MEDI4736 (Durvalumab)” NCT03775486 ↗1“MEDI4736 (durvalumab)” NCT02588131 ↗ |
| Known as | MedImmune 4736 | “MEDI4736 (MedImmune 4736) monotherapy” NCT02527434 ↗ |
| Known as | NSC 778709 | “Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone for Adults With MammaPrint High 2 Risk (MP2) Hormone Receptor (HR) Positive /...” NCT06058377 ↗ |
| Action | Inhibit | “durvalumab (anti-PD-L1)” PMID 33288749 ↗ Dec 2020 |
| Modality | Monoclonal antibody | “MEDI4736 (a monoclonal antibody that targets programmed cell death ligand-1 (PD-L1))” NCT01693562 ↗ |
| Route | Intravenous | “Durvalumab, 1120 mg Q3W, IV for 12 weeks” NCT01042379 ↗ |
| Target | CD274 | “MEDI4736 is an anti-PD-L1 monoclonal antibody (MAb).” NCT02000947 ↗ |